{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ravi P"],"funding":["NCI NIH HHS"],"pagination":["331-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4566003"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(2)"],"pubmed_abstract":["<h4>Background</h4>Approximately a quarter of men with metastatic non-seminomatous germ cell tumor (NSGCT) have a residual mass, typically in the retroperitoneum, after chemotherapy. The management of small residual masses (≤1 cm) is controversial, with good outcomes seen with either post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) or surveillance. We sought to review our experience of surveillance and synthesize the cumulative findings with the current literature in the form of a meta-analysis.<h4>Patients and methods</h4>We searched PubMed, EMBASE and abstracts from ASCO and AUA to identify relevant, English-language studies for the meta-analysis. The DFCI (Dana Farber Cancer Institute) database was constructed from a database of men undergoing cisplatin-based chemother"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor."],"pmcid":["PMC4566003"],"funding_grant_id":["T32 CA009172"],"pubmed_authors":["Gray KP","O'Donnell EK","Ravi P","Sweeney CJ"],"additional_accession":[]},"is_claimable":false,"name":"A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor.","description":"<h4>Background</h4>Approximately a quarter of men with metastatic non-seminomatous germ cell tumor (NSGCT) have a residual mass, typically in the retroperitoneum, after chemotherapy. The management of small residual masses (≤1 cm) is controversial, with good outcomes seen with either post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) or surveillance. We sought to review our experience of surveillance and synthesize the cumulative findings with the current literature in the form of a meta-analysis.<h4>Patients and methods</h4>We searched PubMed, EMBASE and abstracts from ASCO and AUA to identify relevant, English-language studies for the meta-analysis. The DFCI (Dana Farber Cancer Institute) database was constructed from a database of men undergoing cisplatin-based chemother","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Feb","modification":"2026-05-07T17:57:31.447Z","creation":"2026-04-07T23:02:55.909Z"},"accession":"S-EPMC4566003","cross_references":{"pubmed":["24276027"],"doi":["10.1093/annonc/mdt425"]}}